TII
Technology Innovation Institute (TII), the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), today announced the appointment of international experts in the field of systems security to the Board of Advisors of its Secure Systems Research Centre (SSRC).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210308005482/en/
Secure Systems Research Centre is one of the initial seven dedicated centres at TII and is among the few global centres of its kind to bring together experts to conduct groundbreaking research in the field of secure systems. The distinguished new Board have combined expertise in security and resilience relating to autonomous computing and will guide the efforts of the Centre’s research team in developing end-to-end solutions to protect cyber-physical and autonomous systems.
The Board of Advisors comprises:
Prof. Ernesto Damiani, Professor, Department of Electrical Engineering and Computer Science, Senior Director, Artificial Intelligence & Intelligent Systems Institute, Director of the Center for Cyber Physical Systems (C2PS), Khalifa University in the UAE, whose research interests include secure service-oriented architectures, privacy-preserving big data analytics and cyber-physical systems security.
Dr Hoda Alkhzaimi, Research Assistant Professor at New York University Abu Dhabi (NYUAD) and Director of the University’s Center of Cyber Security, who was associated with research and development posts in cybersecurity and cryptology. Her research interests include unmanned aerial vehicle (UAV) security, cryptology, cryptanalysis, and building security hardware and software components.
Dr Bushra Alblooshi, Head of Research and Innovation at Dubai Electronic Security Center (DESC), who is focused on researching cloud computing, cybersecurity, computer forensics and cryptography.
Prof. Inseok Hwang, Professor at the School of Aeronautics and Astronautics at Purdue University, who specialises in research on intelligent and high assurance autonomy for cyber-physical systems with applications to complex networked systems, such as multi-vehicle systems.
Prof. Dongyan Xu, Samuel D. Conte Professor of Computer Science at Purdue University, specialises in research focused on cyber and cyber-physical security.
Prof. Taesoo Kim is Associate Professor at the School of Computer Science at the Georgia Institute of Technology, and his research interests span systems security architecture and design, threat intelligence, internet infrastructure and operating systems, machine learning, and programming languages.
Prof. Wenke Lee is Professor of Computer Science and John P. Imlay Jr. Chair, College of Computing at the Georgia Institute of Technology, and is one of the most prolific and influential cybersecurity researchers in the world. His research specialty is systems and network security, applied cryptography and machine learning.
Dr Harry Edelman is CEO of architectural consultancy Edelman Group and co-founder of AIDOMUS, a machine learning and IoT-based startup initiative for smart urban services. His work has focused on various aspects of integrated urban developments, including smart urban energy design and mobility.
Dr Shreekant (Ticky) Thakkar, Chief Researcher at Secure Systems Research Centre, said: “The Centre combines fundamental and applied research to set new standards and act as a catalyst to transform problems into solutions. The goal of the research team is to create new technologies for the development of end-to-end security and resilience in cyber-physical and autonomous systems.”
Research in security and resilience in cyber-physical and autonomous systems will ultimately lead to groundbreaking efforts in ensuring the safety and economic prosperity of our communities. The Board of Advisors will guide the expert SSRC researchers in carrying out such cutting-edge research while also creating new opportunities to train aspiring young UAE nationals in these significant fields.
For more information about Secure Systems Research Centre (SSRC), visit tii.ae/securesystems
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20210308005482/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom